Form 4: Biohaven Director Acquires Stock Options
SEC Form 4
Director Michael Thomas Heffernan acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025.
Summary
- On May 5, 2025, Michael Thomas Heffernan, a director of Biohaven Ltd., acquired 31,716 stock options.
- The exercise price of these options is $22.62.
- The options vest on the earlier of May 5, 2026, or the date of the 2026 Annual Meeting of Shareholders, contingent upon continuous service with the issuer.
- The options expire on May 5, 2035.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing regarding stock option grants.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in executive compensation within the biotechnology industry.
Stakeholder Impact
- The acquisition of stock options by a director can align their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/05/2025 | Date of transaction: Director acquired stock options. |
| 05/05/2026 | Earliest vesting date for the stock options. |
| 05/07/2025 | Date of Form 4 filing. |
| 05/05/2035 | Expiration date for the stock options. |
Keywords
stock options, Biohaven, director, acquisition, BHVN, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.